PEG [SN22]4
Alternative Names: Camptothecin derivative - PEEL Therapeutics; PEEL-224; Polymer based prodrug of SN22 - PEEL TherapeuticsLatest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator The Childrens Hospital of Philadelphia
- Developer PEEL Therapeutics
- Class Antineoplastics; Camptothecins; Indoles; Piperidines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Dec 2024 Peel Therapeutics plans a phase I/II trial for Solid tumours (Combination therapy, Second-line therapy or greater, In children, In adolescents, In adults) in USA (IV) (NCT06721689)
- 29 Nov 2024 Dana-Farber Cancer Institute and Peel Therapeutics plans phase-I/II trial for Sarcoma (Second-line therapy or greater, Combination therapy, In adolescents, In adults) in USA (IV, infusion) (NCT06709495),
- 01 Nov 2023 Pharmacodynamics data from preclinical studies in Solid tumours released by Peel Therapeutics